A discounted chemical heavyweight targets $1.5bn in recurring EBITDA by 2028

Few sectors punish timing mistakes as harshly as chemicals. Not because the assets lack quality, but because earnings are tightly linked to the cycle—energy costs, global demand, and industry-wide capacity discipline. This company sits precisely at that inflection point: operationally sound, reporting weak results, while management speaks openly about billion-dollar EBITDA improvements in an environment that has yet to turn.

The past two years represent one of the toughest backdrops a global chemical group can face. Soft demand for durables, elevated European energy costs, new capacity coming online in Asia, and compressed margins across petrochemical chains have all weighed on performance. Yet the balance sheet has held up, and structural actions taken during the downturn are intended to reshape the earnings profile once conditions normalize.

Top points of the analysis

• The firm is targeting $1.5bn of recurring EBITDA per year by 2028, largely from internal measures.

• The chemical cycle is…